1887

Journal of Medical Microbiology logo

Volume 53, Issue 12

Quantification and assessment of viability of by LightCycler amplification of capsule gene mRNA Free

Abstract

is an opportunistic fungal pathogen. It infects the central nervous system causing meningitis, which is fatal if untreated, especially in AIDS and immunosuppressed patients. In this study a method of quantification and assessment of viability of by LightCycler RT-PCR amplification of the capsule gene mRNA is established. The sequence of primers and probes were derived from capsular CAP10 gene mRNA (GenBank accession number AF144574), and were species specific. Agarose gel electrophoresis analysis of LightCycler RT-PCR product showed a single band of 223 bp in length. In order to develop an internal control a 223 bp exon fragment of capsule mRNA was cloned in the pCR2.1 plasmid vector and RNA was generated by transcription. To determine the sensitivity of the assay, serial dilutions of -transcribed RNA with known concentrations and copy numbers, and serially diluted cultures of viable and nonviable were used. Under optimal conditions as little as 0.472 fg of capsule mRNA could be detected, corresponding to 1–10 c.f.u. ml of the sample. No amplification was observed from up to10 heat/UV radiation-killed yeast cells and RNA of other bacterial and fungal pathogens and human genomic DNA or RNA. The amplification of capsule mRNA represents a sensitive, specific and quantitative means of detection of viable in clinical specimens and can be useful in the evaluation of the therapeutic efficacy of antifungal drugs in the treatment of meningitis.

  • Received:
  • Accepted:
  • Published Online:
© Microbiology Society
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.45742-0
2004-12-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jmm/53/12/JM531205.html?itemId=/content/journal/jmm/10.1099/jmm.0.45742-0&mimeType=html&fmt=ahah

References

  1. Abadi J., Nachman S., Kressel A. B., Pirofski L. 1999; Cryptococcosis in children with AIDS. Clin Infect Dis 28:309–313 [CrossRef]
     [Google Scholar]
  2. Bialek R., Weiss M., Bekure-Nemariam K., Najvar L. K., Alberdi M. B., Graybill J. R., Reischl U. 2002; Detection of Cryptococcus neoformans DNA in tissue samples by nested and real-time PCR assays. Clin Diagn Lab Immunol 9:461–469
     [Google Scholar]
  3. Blevins L. B., Fenn J., Segal H., Newcomb-Gayman P., Carroll K. C. 1995; False-positive cryptococcal antigen latex agglutination caused by disinfectants and soaps. J Clin Microbiol 33:1674–1675
     [Google Scholar]
  4. Buchanan K. L., Murphy J. W. 1998; What makes Cryptococcus neoformans a pathogen?. Emerg Infect Dis 4:71–83 [CrossRef]
     [Google Scholar]
  5. Bustin S. A. 2000; Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J Mol Endocrinol 25:169–193 [CrossRef]
     [Google Scholar]
  6. Bustin S. A. 2002; Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): trends and problems. J Mol Endocrinol 29:23–39 [CrossRef]
     [Google Scholar]
  7. Chang Y. C., Kwon-Chung K. J. 1999; Isolation, characterization, and localization of a capsule-associated gene, CAP10, of Cryptococcus neoformans . J Bacteriol 181:5636–5643
     [Google Scholar]
  8. Frade J. P., Warnock D. W., Arthington-Skaggs B. A. 2004; Rapid quantification of drug resistance gene expression in Candida albicans by reverse transcriptase LightCycler PCR and fluorescent probe hybridization. J Clin Microbiol 42:2085–2093 [CrossRef]
     [Google Scholar]
  9. Franzot S. P., Salkin I. F., Casadevall A. 1999; Cryptococcus neoformans var. grubii : separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 37:838–840
     [Google Scholar]
  10. Gade W., Hinnefeld S. W., Babcock L. S., Gilligan P., Kelly W., Wait K., Greer D., Pinilla M., Kaplan R. L. 1991; Comparison of the PREMIER cryptococcal antigen enzyme immunoassay and the latex agglutination assay for detection of cryptococcal antigens. J Clin Microbiol 29:1616–1619
     [Google Scholar]
  11. Garcia-Hermoso D., Janbon G., Dromer F. 1999; Epidemiological evidence for dormant Cryptococcus neoformans infection. J Clin Microbiol 37:3204–3209
     [Google Scholar]
  12. Gelmini S., Tricarico C., Petrone L., Forti G., Amorosi A., Dedola G. L., Serio M., Pazzagli M., Orlando C. 2003; Real-time RT-PCR for the measurement of prostate-specific antigen mRNA expression in benign hyperplasia and adenocarcinoma of prostate. Clin Chem Lab Med 41:261–265
     [Google Scholar]
  13. Goldman D. L., Khine H., Abadi J., Lindenberg D. J., Pirofski L., Niang R., Casadevall A. 2001; Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107, E66. E66: [CrossRef]
     [Google Scholar]
  14. Kaucner C., Stinear T. 1998; Sensitive and rapid detection of viable Giardia cysts and Cryptosporidium parvum oocysts in large-volume water samples with wound fiberglass cartridge filters and reverse transcription-PCR. Appl Environ Microbiol 64:1743–1749
     [Google Scholar]
  15. Kralovic S. M., Rhodes J. C. 1998; Utility of routine testing of bronchoalveolar lavage fluid for cryptococcal antigen. J Clin Microbiol 36:3088–3089
     [Google Scholar]
  16. Kwon-Chung K. J., Bennett J. E. 1984; Epidemiologic differences between the two varieties of Cryptococcus neoformans . Am J Epidemiol 120:123–130
     [Google Scholar]
  17. Luo G., Mitchell T. G. 2002; Rapid identification of pathogenic fungi directly from cultures by using multiplex PCR. J Clin Microbiol 40:2860–2865 [CrossRef]
     [Google Scholar]
  18. Maher N. H., Vermund S. H., Welsh D. A., Dillon H. K., Awooda A., Unnasch T. R. 2001; Development and characterization of a molecular viability assay for Pneumocystis carinii f sp hominis . J Infect Dis 183:1825–1827 [CrossRef]
     [Google Scholar]
  19. Mitchell T. G., Freedman E. Z., White T. J., Taylor J. W. 1994; Unique oligonucleotide primers in PCR for identification of Cryptococcus neoformans . J Clin Microbiol 32:253–255
     [Google Scholar]
  20. Miyoshi Y., Ando A., Takamura Y., Taguchi T., Tamaki Y., Noguchi S. 2002; Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129–132 [CrossRef]
     [Google Scholar]
  21. Okeke C. N., Tsuboi R., Kawai M., Yamazaki M., Reangchainam S., Ogawa H. 2000; Reverse transcription – 3′ rapid amplification of cDNA ends-nested PCR of ACT1 and SAP2 mRNA as a means of detecting viable Candida albicans in an in vitro cutaneous candidiasis model. J Invest Dermatol 114:95–100 [CrossRef]
     [Google Scholar]
  22. Okeke C. N., Tsuboi R., Ogawa H. 2001; Quantification of Candida albicans actin mRNA by the LightCycler system as a means of assessing viability in a model of cutaneous candidiasis. J Clin Microbiol 39:3491–3494 [CrossRef]
     [Google Scholar]
  23. Peters I. R., Helps C. R., Hall E. J., Day M. J. 2004; Real-time RT-PCR: considerations for efficient and sensitive assay design. J Immunol Methods 286:203–217 [CrossRef]
     [Google Scholar]
  24. Prariyachatigul C., Chaiprasert A., Meevootisom V., Pattanakitsakul S. 1996; Assessment of a PCR technique for the detection and identification of Cryptococcus neoformans . J Med Vet Mycol 34:251–258 [CrossRef]
     [Google Scholar]
  25. Rappelli P., Are R., Casu G., Fiori P. L., Cappuccinelli P., Aceti A. 1998; Development of a nested PCR for detection of Cryptococcus neoformans in cerebrospinal fluid. J Clin Microbiol 36:3438–3440
     [Google Scholar]
  26. Saag M. S., Graybill R. J., Larsen R. A., Pappas P. G., Perfect J. R., Powderly W. G., Sobel J. D., Dismukes W. E. 2000; Practice guidelines for the management of cryptococcal disease.Infectious Diseases Society of America. Clin Infect Dis 30:710–718 [CrossRef]
     [Google Scholar]
  27. Stordeur P., Poulin L. F., Craciun L., Zhou L., Schandene L., de Lavareille A., Goriely S., Goldman M. 2002; Cytokine mRNA quantification by real-time PCR. J Immunol Methods 259:55–64 [CrossRef]
     [Google Scholar]
  28. Tanaka K., Miyazaki T., Maesaki S. & 7 other authors; 1996; Detection of Cryptococcus neoformans gene in patients with pulmonary cryptococcosis. J Clin Microbiol 34:2826–2828
     [Google Scholar]
  29. Tintelnot K., Adler S., Bergmann F., Schonherr K., Seibold M. 2000; Case reports.Disseminated cryptococcoses without cryptococcal antigen detection. Mycoses 43:203–207 [CrossRef]
     [Google Scholar]
  30. Warren N. G., Hazen K. C. 1999; Candida , Cryptococcus , and other yeasts of medical importance. In Manual of Clinical Microbiology pp 1184–1200, 7th edn. Edited by Murray P. R., Baron E. J., Pfaller M. A., Tenover F. C., Yolken R. H. Washington, DC: American Society for Microbiology;
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.45742-0
Loading
Quantification and assessment of viability of Cryptococcus neoformans by LightCycler amplification of capsule gene mRNA
J. Med. Microbiol. 53, 1201 (2004); https://doi.org/10.1099/jmm.0.45742-0
/content/journal/jmm/10.1099/jmm.0.45742-0
/content/journal/jmm/10.1099/jmm.0.45742-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error